At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 1,104 enrolled
Drug / intervention
Dapivirine (DPV) Vaginal Ring (VR) +1 moredrug
Likely dose
Dapivirine (DPV) Vaginal Ring (VR) 25 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase 3b, Randomized, Open Label Safety Trial of Dapivirine Vaginal Ring and Oral TRUVADA® Use in Pregnancy
National Institute of Allergy and Infectious Diseases (NIAID)·interventional·Posted May 29, 2019·Updated Aug 12, 2025
In Brief
A Phase 3 clinical trial evaluating Dapivirine (DPV) Vaginal Ring (VR) and Truvada Tablet for HIV Infections. Completed, enrolled 1,104 participants across 4 sites in 4 countries.
Detailed Summary
The purpose of this study is to evaluate the maternal and infant safety of the dapivirine (DPV) vaginal ring (VR) and daily oral Truvada in HIV-uninfected pregnant women and their infants.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHIV Infections
CountriesMalawi, South Africa, Uganda, Zimbabwe
Collaborators--
Timeline
Phase 3CompletedFinished
2020202120222023202420252026
First PostedMay 2019
Enrollment StartJan 2020
Primary CompletionMay 2024
TodayJul 2026
First PostedMay 29, 2019
Enrollment StartJan 9, 2020
Primary CompletionMay 13, 2024
TodayJul 2, 2026
Enrollment to primary: 4.3 yearsPosted 7.1 years ago
Interventions
Dapivirine (DPV) Vaginal Ring (VR)drug
Vaginal ring containing 25 mg of DPV
Truvada Tabletdrug
Tablet taken orally